Tibet pharmaceutical Industry by agents Kangjie drug industry licensing is referred to the sole agency paving the road

After the opening of the Spring Festival, the Tibetan medicine (market, interrogation) price rose for several consecutive days, as of February 13 cumulative increase of 37%. Market rumors, and shareholders and agents Shenzhen Kangjie Pharmaceutical Co., Ltd. (hereinafter referred to as "Kangjie pharmaceutical") is closely related. Yesterday, the truth finally surfaced, Kangjie Medicine and its concerted action to buy Tibetan medicine, the proportion of the latter's total share capital of 5%, constitute a card. Surprise increase in the composition of the card yesterday, the Tibetan medicine issued a notice, the company received Kangjie pharmaceutical notice, February 13, 2014, Kangjie Pharmaceutical industry through the two-level market accumulated increased by 306,800 shares, an increase in the average price of 25.26 yuan/shares, accounting for the company's total capital of 0.21%. After overweight, the Kangjie pharmaceutical industry and its concerted action person total holds 7.2795 million shares, the shareholding proportion achieves the company Total share capital 5%, constitutes the lifting card. According to the disclosure of information, Kangjie Pharmaceutical and Tianjin Kangjie Pharmaceutical Technology Development Co., Ltd., Shenzhen Kangjie Pharmaceutical Technology Development Co., Ltd. for the concerted action. Before the change of interest, 3 companies owned 6.9727 million shares of Tibet pharmaceutical industry, accounting for 4.79% of total equity. After the overweight, 3 companies held 2.1255 million shares, 3.5917 million shares, 1.5622 million shares, accounting for 5% of the company's total equity. Kangjie said that the overweight is due to financial investment and deepen the cooperation with the Tibetan medicine industry. At the same time, it does not rule out the possibility of continuing to increase or reduce the holdings in the next 12 months. Affected by this news, the Tibetan medicine industry opened yesterday and sealed the trading board. "Discontinued" Product inventory sufficient horse since the opening, the Tibetan medicine shares all the way up, harvesting a number of trading board. The market has been rumored that the stock price rally and Kangjie pharmaceutical industry to continue to obtain the future of the agency of the new living element is closely related. Data show that Kangjie pharmaceutical industry as a former agent of Tibet Pharmaceutical. 2008 Tibet Pharmaceutical Industry and Kangjie pharmaceutical industry has signed the "New Living element sole Agent general distribution Framework Agreement", but the agreement was completed on December 31, 2013. The company said that at present, Kangjie pharmaceutical industry is still continuing to sell this product, about the next step of the cooperation between the two sides are still in talks, has not signed any formal agreement. In addition, because of the Tibet pharmaceutical BNP freeze dry preparation production line renovation work is underway, plans to obtain GMP certification before March 2015. The original BNP lyophilized preparation production line was discontinued on December 31, 2013. Companies in the previous market estimates, production of adequate products to ensure the completion of the new production line before the market demand, the production of the company's operating conditions will not have a big impact. "Kangjie pharmaceutical industry in the new agreement has not signed before the surprise increase, its intention is obvious, but after the agreement is to leave is not good to say, the commitment is also ' or buy or sell '. One investor told the Public Securities Journal. Reporters with the doubts of investors call Tibet pharmaceutical industry, a staff of the Secretary for the Secretary is not on the basis of the refusal to interview.